Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06481150 · ClinicalTrials.gov registry record · Phase 4
A Novel Approach for Reducing Hyperoxaluria and Kidney Stone Risk.
A Phase 4 study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 18
- Enrollment target
NCT06481150 is a Phase 4 study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 18 participants.
The verdict
NCT06481150, a Phase 4 study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 18 participants
- Enrollment target
Study Summary
This pilot study is proposing a novel approach to directly target intestinal oxalate absorption with the drug Tenapanor, which was recently FDA-approved for treating hyperphosphatemia in patients with chronic kidney disease. Tenapanor works by blocking paracellular phosphate absorption by the intestine, but the underlying mechanisms have not been clearly defined. Since phosphate and oxalate ions are absorbed through the same paracellular pathway, and are of similar size and charge, Tenapanor is hypothesized to also reduce dietary oxalate absorption and consequently lower urinary oxalate excretion.
Interventions
- OTHER Placebo
- DRUG Tenapanor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2024-07-01 |
| Est. Completion | 2025-09-14 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06481150
The ClinicalTrials.gov registry entry for NCT06481150 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06481150 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06481150 about?
NCT06481150 is a clinical study titled "A Novel Approach for Reducing Hyperoxaluria and Kidney Stone Risk.". This pilot study is proposing a novel approach to directly target intestinal oxalate absorption with the drug Tenapanor, which was recently FDA-approved for treating hyperphosphatemia in patients with chronic kidney disease. Tenapanor works by blocking paracellular phosphate absorption by the intest...
What is the current status of trial NCT06481150?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 18 participants. The study started on 2024-07-01. Estimated completion is 2025-09-14.
What interventions are being tested in trial NCT06481150?
The interventions under investigation include: Placebo (OTHER), Tenapanor (DRUG).
Who is sponsoring clinical trial NCT06481150?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.